Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Aeterna Zentaris Inc (AEZS.TO)
Aeterna Zentaris Inc (AEZS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aeterna Zentaris Inc 222 Bay Street Suite 3000, PO Box 53 Toronto ON M5K 1E7 CAN

https://www.zentaris.com

Description:

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

Key Statistics

Overview:

Market Capitalization, $K 12,771
Shares Outstanding, K 4,856
Annual Sales, $ 5,640 K
Annual Net Income, $ -22,727 K
Last Quarter Sales, $ 3 K
Last Quarter Net Income, $ -4,145 K
60-Month Beta 1.31
% of Institutional Shareholders 0.08%

Growth:

1-Year Return -43.64%
3-Year Return -91.08%
5-Year Return -97.86%
5-Year Revenue Growth 43.62%

Per-Share Information:

Most Recent Earnings -0.85 on 11/09/23
Latest Earnings Date 03/28/24
Earnings Per Share ttm -4.81
EPS Growth vs. Prev Year 78.15%
Annual Dividend Rate, $ 0.00
Most Recent Dividend 1,237.498 on 08/11/99
Next Ex-Dividends Date 08/11/99
Dividend Payable Date 01/01/70
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 07/21/22

AEZS.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -61.74%
Return-on-Assets % -42.84%
Profit Margin % -402.96%
Debt/Equity 0.00
Price/Sales 1.37
Price/Book 0.36
Book Value/Share 7.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar